Udit Verma

Udit Verma oversees cell therapy process development at Bristol Myers Squibb, where he has led efforts to optimize the manufacturing process for lisocabtagene maraleucel and next-generation CAR-T products. His team has developed improved T cell enrichment and activation strategies that increase manufacturing success rates across diverse patient populations including those with poor T cell fitness. He is advancing continuous manufacturing approaches that promise to reduce production costs and turnaround times.